<DOC>
	<DOCNO>NCT01167725</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop dividing . Heating mitomycin C several degree normal body temperature infuse area around tumor may kill tumor cell . Giving mitomycin C surgery may kill remain tumor cell . It yet know whether standard therapy effective without surgery follow mitomycin C. PURPOSE : This randomized phase III trial study standard therapy without surgery mitomycin C treat patient advance limited peritoneal dissemination colon cancer</brief_summary>
	<brief_title>Standard Therapy With Without Surgery Mitomycin C Treating Patients With Advanced Limited Peritoneal Dissemination Colon Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare overall survival ( OS ) patient advance limited peritoneal dissemination colon adenocarcinoma treat systemic therapy v without cytoreduction surgery hyperthermic intraperitoneal mitomycin C. - To compare relative OS 1 year patient treat regimen . Secondary - To compare progression-free survival ( PFS ) patient treat regimen . - To compare relative PFS 1 year patient treat regimen . - To compare quality life patient treat regimen . - To compare toxicity burden regimens patient . - To compare OS PFS accord patient ' peritoneal surface tumor genotype NAD ( P ) H ( quinone oxidoreductase 1 [ NQO1 ] 609C &gt; T polymorphism [ wild type v heterozygous/homozygous mutant ] ) patient treat regimen . - To compare circulate tumor cell patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord presentation ( synchronous v metachronous carcinomatosis ) , ECOG performance status ( 0 vs 1 ) , disease volume ( measurable v non-measurable ) , prior first-line therapy advance disease ( chemo-naïve v prior first-line therapy ) , plan chemotherapy ( oxaliplatin v irinotecan v fluorouracil/leucovorin calcium v capecitabine ) , plan biologic therapy ( bevacizumab v cetuximab v none ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive standard systemic therapy , discretion patient ' oncologist , comprise combination fluorouracil , leucovorin calcium , irinotecan hydrochloride , oxaliplatin , and/or capecitabine ( include FOLFOX4 , mFOLFOX6 , CapeOx , FOLFIRI ) without bevacizumab ( begin 4-6 week major surgery ) cetuximab* . Treatment repeat absence disease progression unacceptable toxicity . Patients progressive disease may crossover arm II . NOTE : *For patient KRAS wild-type tumor . - Arm II : Patients undergo cytoreduction surgery hyperthermic intraperitoneal mitomycin C 45-90 minute . Beginning 8 week surgery , patient receive standard systemic therapy arm I . Treatment systemic therapy repeat 6 course absence disease progression unacceptable toxicity . Blood tissue sample may collect patient correlative study . Patients complete SF-36 Health Survey ; Functional Assessment Cancer Therapy-Colorectal ( FACT-C ) ; Feeling Sad , Down , Depressed ( CES-D ) ; Brief Pain Inventory quality-of-life questionnaire baseline periodically study . After completion study therapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm colon adenocarcinoma meeting follow criterion : Newly diagnose disease Advanced disease Confirmed synchronous metachronous limited peritoneal disease dissemination No appendiceal rectal cancer No signet ring cell type Disease amenable complete cytoreduction surgery indicate : Peritoneal Cancer Index ( PCI ) ≤ 20 helical CT scan and/or stag laparoscopy No parenchymal hepatic metastases No clinical ( jaundice ) , biochemical ( abnormally elevate serum bilirubin and/or alkaline phosphatase ) , radiological ( ultrasound , CT scan , MRI ) biliary obstruction No symptomatic malignant ascites require palliative paracentesis Small volume disease gastrohepatic ligament define &lt; 5 cm mass epigastric region crosssectional imaging No crosssectional imaging finding indicative multisegmental ( &gt; 1 site ) small bowel obstruction , small bowel loop mat together , gross disease small bowel mesentery characterize distortion , thicken , loss mesenteric vascular clarity No clinical radiological evidence hematogenous distant nodal ( retroperitoneal , pelvic , mediastinal , periportal , periaortic ) metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 ANC &gt; 1,200/mm³ WBC &gt; 4,000/mm³ Platelet count 150,000/mm³ INR ≤ 1.5 Patients therapeutic anticoagulant unrelated medical condition atrial fibrillation antithrombocyte treatment allow provide treatment withheld operation Total serum bilirubin ≤ 1.5 mg/dL ( &gt; 1.5 mg/dL patient Gilbert syndrome ) Alkaline phosphatase &lt; 2.5 time upper limit normal ( ULN ) AST &lt; 1.5 time ULN Serum creatinine normal BUN normal Not pregnant nursing Fertile patient must use effective contraception No history severe congestive heart failure severe pulmonary disease Patients status postrevascularization procedure satisfactory cardiac function eligible No acute myocardial infarction within past 6 month No significant history medical problem comorbidity ( e.g. , severe congestive heart failure active ischemic heart disease ) would preclude major abdominal operation No concurrent second malignancy require systemic therapy No psychiatric addictive disorder , condition would preclude patient meeting study requirement PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior secondline systemic treatment metastatic colon adenocarcinoma Patients receive prior adjuvant therapy colon adenocarcinoma and/or prior firstline systemic therapy metastatic colon adenocarcinoma eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>mucinous adenocarcinoma colon</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
</DOC>